about
Antipsychotic dose escalation as a trigger for neuroleptic malignant syndrome (NMS): literature review and case series reportNeuroleptic malignant syndrome: a review for neurohospitalistsNeuroleptic malignant syndrome induced by atypical antipsychotics.Fluphenazine-induced neuroleptic malignant syndrome in a schizophrenic patient.Association between selective serotonin-reuptake inhibitors, second-generation antipsychotics, and neuroleptic malignant syndrome.Neuroleptic malignant syndrome secondary to quetiapine.Immune dysregulation and autoimmunity in bipolar disorder: Synthesis of the evidence and its clinical application.Preventive strategies and potential therapeutic interventions for delirium in sepsis.Psychosis in Parkinson Disease: A Review of Etiology, Phenomenology, and Management.[Prolonged neuroleptic malignant syndrome after Haloperidol injection].Neuroleptic Malignant Syndrome: A Case Aimed at Raising Clinical Awareness.Olanzapine-associated neuroleptic malignant syndrome in a patient receiving concomitant rivastigmine therapy.Neuroleptic malignant syndrome with severe liver failure.Neuroleptic Malignant Syndrome: Complications, Outcomes, and Mortality.B-lymphocytes from malignant hyperthermia-susceptible patients have an increased sensitivity to skeletal muscle ryanodine receptor activators.Propofol-remifentanil combination for management of electroconvulsive therapy in a patient with neuroleptic malignant syndrome.Malignant neuroleptic syndrome following deep brain stimulation surgery: a case report.Neuroleptic malignant syndrome in a patient with tongue cancer: a report of a rare case.[Rhabdomyolysis and myoglobinuria].Infections as complications of neuroleptic malignant syndrome.Recurrent heat-related illnesses during antipsychotic treatment.Anesthetic management of a pediatric patient with neuroleptic malignant syndrome.Postoperative neuroleptic malignant syndrome that occurred repeatedly in a patient with cerebral palsy.Malignant brain stem hyperthermia caused by submersion-related hypoxic encephalopathy.Suspected malignant hyperthermia in a child with laminin alpha2 (merosin) deficiency in the absence of a triggering agent.Neuroleptic Malignant Syndrome.Pharmacist intervention to detect drug adverse events on admission to the emergency department: Two case reports of neuroleptic malignant syndrome.
P2860
Q27012733-5ADCB21E-113C-48B5-9C83-27FCADBBD56DQ34367132-E8B56B88-60D4-4B4B-BA20-8783B8FB53DBQ35194436-DBAFF14F-548E-4345-88D8-348F26DF238DQ36102513-EAB8E769-4A1D-4C84-B0A4-881EAB486295Q37217134-0268BF38-4842-437E-9BAA-C7C8BE644BE1Q37418522-7C9857AF-9B36-4A0B-AC0E-E3A35F66BCF5Q38125979-609A4CEB-9503-4D60-A20A-7AD48E33074AQ38862634-02D73C1E-0C23-4D29-A4E8-91B56D58DD14Q39004255-EBCDB7F4-838A-48EC-A10C-C989D2190082Q40045768-59548551-9742-4C74-8935-B4C2F84B91F8Q40147479-F039B67A-701D-4828-BD48-B1A33F1881F2Q40426437-46BE5B13-88BB-488A-B539-30A116983B6AQ40552886-8120F49B-2121-4181-8D0B-9D9DDF4D8C9BQ40681278-15988003-7696-424A-A7AF-D34431429D80Q40773131-87EE20A1-B1F6-4FB0-BC85-EEAE8307EEDAQ42079647-FCC7F219-9DA7-4D48-B990-68FD58DF9302Q42839805-CF9D1048-5354-481A-8286-A6DB9EA5E09DQ43103870-E437986B-D83E-42EA-AA76-4102923E90F0Q44473855-33A922E7-5B66-43D0-AA20-5B13C2E0F242Q46495728-C5D31815-0D87-472D-AB1E-6193974C4AEBQ46713414-9EBC5A24-F539-4BAC-BFDF-5629B16F134AQ48212385-562832AA-1ACD-4809-9EB9-8E6797CB8995Q48625436-F9F12C18-DD6F-4266-B4B8-AC72BDD3D788Q48649445-295C6790-F82C-4829-9918-769F6EA60AA0Q48707597-2480F118-EDDC-40E7-B7CA-28D4E8343A3CQ52991012-AB22FB22-DE74-4FE6-9162-A920BA1B55FBQ53303074-84910275-CE62-452A-8C27-0ADFDDF200FE
P2860
description
2000 nî lūn-bûn
@nan
2000 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
Neuroleptic malignant syndrome
@en
type
label
Neuroleptic malignant syndrome
@en
prefLabel
Neuroleptic malignant syndrome
@en
P2093
P356
P1476
Neuroleptic malignant syndrome
@en
P2093
P Lestavel
R Krivosic-Horber
P304
P356
10.1093/BJA/85.1.129
P407
P577
2000-07-01T00:00:00Z